Please assess the completion status of the following clinical trial:

Trial Title: Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Gail risk \>= 1.7% and/or relative risk \>= 3 times that for 5-year age group~* Premenopausal~* More than 6 months since initiating or discontinuing oral contraceptives~* At increased risk for breast cancer, as indicated by \>= 1 of the following risk factors:~* BRCA1/2 mutation characterized as deleterious or of uncertain significance~* Prior atypical ductal hyperplasia, ductal carcinoma in situ, or lobular carcinoma in situ~* Prior random periareolar fine needle aspiration (RPFNA) showing atypical hyperplasia~* Family history consistent with hereditary breast cancer, as indicated by 1 of the following criteria:~  * \>= 4 relatives with breast cancer~ * \>= 2 relatives diagnosed with breast cancer at ≤ 50 years of age~ * Breast and ovarian cancer diagnosed in same relative~* No suspicion for breast cancer on baseline mammogram performed between days 1-10 of menstrual cycle within 3 months prior to screening baseline RPFNA~* Exhibits hyperplasia with or without atypia (Masood score \>= 14) with \>= 500 cells AND Ki-67 positivity \>= 2% by RPFNA performed within 6 months prior to initiation of study drug~* Estimated visual mammographic breast density category \>= 5% on mammogram performed within 6 months prior to initiation of study drug~* Has regular menstrual cycles (between 21 and 35 days) unless using extended regimen oral contraceptives or a contraceptive device (e.g., Mirena IUD) Values for metabolic profile and blood count within normal limits~* Absolute granulocyte count \> 1,000/mm\^3~* Platelets \> 100,000/mm\^3~* Hemoglobin \> 10 g/dL~* Bilirubin \< 2.0 mg/dL~* AST \< 2 times upper limit of normal (ULN)~* Albumin \> 3.0 g/dL~* Creatinine \< 1.5 mg/dL~* Alkaline phosphatase \< 2 times ULN~* Concurrent hormonal contraceptives allowed provided patient remains on the same hormonal regimen from 3 months prior to baseline aspiration until the completion of study treatment~* Fertile patients must use effective contraception during and for 3 months after completion of study treatment~* Willing to ingest recommended dose of calcium and vitamin D for premenopausal bone health (1,200 mg calcium and 800 IU vitamin D daily)~* Negative pregnancy test prior to receiving study agent~Exclusion Criteria~* pregnant or nursing~* nursing within the past 6 months~* Known osteoporosis or severe osteopenia (T-score -2 or worse by DEXA)~* History of symptomatic endometriosis with pelvic pain, poorly controlled migraines, or hot flashes~* History of deep venous thrombosis~* History of allergic reactions attributed to compounds of similar chemical or biological composition to the study agent~* Other condition or concurrent illness that, in the opinion of the investigator, would make the patient a poor candidate for RPFNA~* Less than 1 year since prior use of aromatase inhibitors (e.g., anastrozole, exemestane, or letrozole) or selective estrogen receptor modulators (e.g., tamoxifen citrate, raloxifene, or arzoxifene hydrochloride)~* Other concurrent chemopreventive agents~* Concurrent anticoagulants~* Other concurrent investigational agents~* Bilateral breast implants

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Prevention (acolbifene hydrochloride) (Type: EXPERIMENTAL): Patients receive oral acolbifene hydrochloride once daily for 6 months in the absence of unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete